person · Reporting owner

WILLS STEPHEN T

Disclosed activity across 6 companies

Tapewire entity: 29911
SEC CIK: 0001103883

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cactus Acquisition Corp. 1 LtdCCTSU · Entity 88589	Chief Financial Officer	October 28, 2021	November 03, 2021
Gamida Cell Ltd.GMDA · Entity 94655	Director	January 31, 2024	February 02, 2024
MediWound Ltd.MDWD · Entity 296	Director	March 18, 2026	March 18, 2026
PALATIN TECHNOLOGIES INCPTN · Entity 7649	Executive VP and CFO/COO	July 15, 2026	July 17, 2026
Viskase Holdings, Inc.ENZN · Entity 7040	Director	January 07, 2025	January 10, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cactus Acquisition Corp. 1 Ltd

Report date October 28, 2021 · Filed November 03, 2021

This filing explicitly reported no securities owned.

Gamida Cell Ltd.

Report date January 31, 2024 · Filed February 02, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	256,177	Reported balance After 2024-01-31 transaction · row 1 1 source row Row 1 · 2024-01-31 · Grant · Acquired 200,000 · Balance 256,177 F1: Represents a restricted share unit award, which shall vest on January 31, 2025, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted share unit award, which shall vest on January 31, 2025, subject to the Reporting Person's continuous service through such vesting date.

MediWound Ltd.

Report date March 18, 2026 · Filed March 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary sharesSEC Table I · non-derivative	Direct	9,679	Reported balance Holding disclosure · report date 2026-03-18 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 9,679
Ordinary sharesSEC Table I · non-derivative	Direct	750	Reported balance Holding disclosure · report date 2026-03-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 750 F1: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $34.43 · Expires 2029-03-24	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed
Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $12.25 · Expires 2030-06-29	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed
Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $37.52 · Expires 2031-06-15	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed
Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $14.42 · Expires 2032-05-16	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed
Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $11.89 · Expires 2033-05-30	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance Not disclosed
Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2034-02-26	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance Not disclosed
Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $18.54 · Expires 2035-02-11	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance Not disclosed
Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $17.60 · Expires 2036-03-04	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · Balance Not disclosed F2: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

F2: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

PALATIN TECHNOLOGIES INC

Report date July 15, 2026 · Filed July 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	63,792	Ending reported balance After 2026-07-15 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-07-15 · Tax withholding · Disposed 22 · Balance 63,965 F1: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended July 15, 2026, with the per share value of $11.77 determined as of June 22, 2026, the date of vesting, for a grant of 79 shares less the 22 shares withheld. Row 2 · 2026-07-15 · Tax withholding · Disposed 79 · Balance 63,886 F2: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended July 15, 2026, with the per share value of $11.72 determined as of June 20, 2026, the date of vesting, for a grant of 287 shares less the 79 shares withheld. Row 3 · 2026-07-15 · Tax withholding · Disposed 94 · Balance 63,792 F3: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended July 15, 2026, with the per share value of $14.34 determined as of June 4, 2026, the date of vesting, for a grant of 345 shares less the 94 shares withheld.

Filing footnotes · ownership attribution and instrument terms

F1: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended July 15, 2026, with the per share value of $11.77 determined as of June 22, 2026, the date of vesting, for a grant of 79 shares less the 22 shares withheld.

F2: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended July 15, 2026, with the per share value of $11.72 determined as of June 20, 2026, the date of vesting, for a grant of 287 shares less the 79 shares withheld.

F3: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended July 15, 2026, with the per share value of $14.34 determined as of June 4, 2026, the date of vesting, for a grant of 345 shares less the 94 shares withheld.

Viskase Holdings, Inc.

Report date January 07, 2025 · Filed January 10, 2025

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

DERMA SCIENCES, INC.

Report date February 24, 2017 · Filed February 24, 2017

Section 16 reporting ended · disclosed 2017-02-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	27,500	Ending reported balance After 2017-02-24 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2017-02-24 · Disposition to issuer · Disposed 147,076 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2017, by and among the Issuer, Integra Derma, Inc. and Integra LifeSciences Holdings Corporation (the "Merger Agreement"), as of the Effective Time (as defined in the Merger Agreement), the shares of the Issuer's common stock were converted into the right to receive $7.00 per share to the reporting person in cash. Row 2 · 2017-02-24 · Disposition to issuer · Acquired 27,500 · Balance 27,500 F2: Represents shares of the Issuer's common stock received upon the vesting of 27,500 restricted stock units, as described herein. F4: In connection with the expiration of the Offer and the subsequent closing of the merger pursuant to the terms of the Merger Agreement, all outstanding stock options became fully vested and exercisable on such date. Each stock option held by the reporting person was then cancelled in exchange for a cash payment representing the difference between the exercise price of such option and $7.00 per share, payable without any interest thereon and subject to any required tax withholdings.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.27	Direct	0	Reported balance After 2017-02-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-02-24 · Disposition to issuer · Disposed 29,375 · Balance 0 F3: Represents the weighted average exercise price for in-the-money stock options, as described in a Schedule TO and the Issuer's Schedule 14D-9, each as filed with the Securities and Exchange Commission on January 25, 2017, pursuant to which Integra Derma, Inc. offered to purchase all of the Issuer's common stock for $7.00 per share (the "Offer"). F6: The options were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration. F4: In connection with the expiration of the Offer and the subsequent closing of the merger pursuant to the terms of the Merger Agreement, all outstanding stock options became fully vested and exercisable on such date. Each stock option held by the reporting person was then cancelled in exchange for a cash payment representing the difference between the exercise price of such option and $7.00 per share, payable without any interest thereon and subject to any required tax withholdings.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2017-02-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-02-24 · Disposition to issuer · Disposed 27,500 · Balance 0 F5: Upon the Effective Time, the restricted stock units were converted into the right to receive an amount in cash equal to $7.00 with respect to each share of common stock underlying such award, payable without any interest thereon and subject to any required tax withholdings. F7: The restricted stock units were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2017, by and among the Issuer, Integra Derma, Inc. and Integra LifeSciences Holdings Corporation (the "Merger Agreement"), as of the Effective Time (as defined in the Merger Agreement), the shares of the Issuer's common stock were converted into the right to receive $7.00 per share to the reporting person in cash.

F2: Represents shares of the Issuer's common stock received upon the vesting of 27,500 restricted stock units, as described herein.

F3: Represents the weighted average exercise price for in-the-money stock options, as described in a Schedule TO and the Issuer's Schedule 14D-9, each as filed with the Securities and Exchange Commission on January 25, 2017, pursuant to which Integra Derma, Inc. offered to purchase all of the Issuer's common stock for $7.00 per share (the "Offer").

F4: In connection with the expiration of the Offer and the subsequent closing of the merger pursuant to the terms of the Merger Agreement, all outstanding stock options became fully vested and exercisable on such date. Each stock option held by the reporting person was then cancelled in exchange for a cash payment representing the difference between the exercise price of such option and $7.00 per share, payable without any interest thereon and subject to any required tax withholdings.

F5: Upon the Effective Time, the restricted stock units were converted into the right to receive an amount in cash equal to $7.00 with respect to each share of common stock underlying such award, payable without any interest thereon and subject to any required tax withholdings.

F6: The options were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration.

F7: The restricted stock units were originally granted in consideration of the reporting person's services to the Issuer and without payment of consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 02, 2017 Filed Feb 3, 2017 21:31 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantCommon Stock	300,000	$0.00	$0.00	Disclosure SEC source: 0001354488-17-000210 · issuerdirect_section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,939,041 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made December 8, 2015, vested on February 2, 2017, upon the Issuer entering into a collaboration agreement for North America for its Rekynda? (bremelanotide) product. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made December 8, 2015, vested on February 2, 2017, upon the Issuer entering into a collaboration agreement for North America for its Rekynda? (bremelanotide) product. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. Read SEC document
September 07, 2016 Filed Sep 8, 2016 20:15 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantStock Option (right to acquire) · Derivative	396,000	$0.00 Strike: $0.68	$0.00	Disclosure SEC source: 0001354488-16-008271 · issuerdirect_section16.xml · derivative · entry 2 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,000 Underlying: Common · 396,000 shares Expires 2026-09-07 F2 · derivative.exercise_date: Options to purchase 182,250 shares vest on September 7, 2017, and the remaining options vest at the rate of 33.3% per year, starting on September 7, 2018. Read SEC document
September 07, 2016 Filed Sep 8, 2016 20:15 UTC	PALATIN TECHNOLOGIES INC PTN · Entity 7649	GrantCommon Stock	268,000	$0.00	$0.00	Disclosure SEC source: 0001354488-16-008271 · issuerdirect_section16.xml · nonDerivative · entry 1 WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,842,041 F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest as to 168,000 shares on September 7, 2017, and as to the remaining shares on September 7, 2018. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest as to 168,000 shares on September 7, 2017, and as to the remaining shares on September 7, 2018. Vested shares, subject to the terms of the applicable restricted share unit agreement, will be delivered following the reporting person ceasing to serve as an employee of Palatin Technologies, Inc. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.